Form 4: Conduit Pharmaceuticals CEO Andrew Regan Boosts Stake via Joint Development Agreement

Conduit Pharmaceuticals Inc. CEO Andrew Regan, through affiliated entities, acquired 154,799 shares of common stock as part of a $500,000 upfront payment for a joint development agreement, increasing his beneficial ownership.

Summary

• Andrew Regan, CEO, Director, and 10% owner of Conduit Pharmaceuticals Inc. (CDT), reported an acquisition of common stock.
• On June 3, 2025, Manoira Corporation, an entity indirectly controlled by Dr. Regan, acquired 154,799 shares of Conduit Pharmaceuticals common stock at a price of $3.23 per share.
• This acquisition represents an upfront consideration of $500,000 under a joint development agreement by and between the Issuer and Manoira Corporation.
• Following this transaction, Dr. Regan's total beneficial ownership, including shares held by Manoira Corporation, Corvus Capital Limited, and Algo Holdings, Inc., as well as directly, amounts to 174,993 shares.
• The reported share numbers have been adjusted to reflect a 1-for-100 reverse stock split on January 24, 2025, and a 1-for-15 reverse stock split on May 15, 2025.

Sentiment

Score: 7

Explanation: The acquisition of shares by the CEO and a significant owner, especially in connection with a joint development agreement, generally indicates confidence and potential positive strategic developments, leading to a moderately positive sentiment.

Positives

• The CEO and a significant owner, Andrew Regan, increased his beneficial ownership in the company, which can signal confidence in future prospects.
• The acquisition of shares is tied to a joint development agreement, suggesting ongoing strategic initiatives and potential future growth.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the execution of a joint development agreement, which implies future collaborative efforts.

Management Comments

• Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus.
• Each of Corvus and Dr. Regan disclaims any such beneficial ownership except to the extent of its or his pecuniary interest therein.

Industry Context

This Form 4 filing indicates an insider transaction within the pharmaceutical industry. The acquisition of shares as part of a joint development agreement suggests strategic collaboration, which is a common practice in the pharmaceutical and biotechnology sectors for R&D and market expansion.

Comparison to Industry Standards

• This document is a standard insider transaction report (Form 4) and does not contain information that allows for a direct comparison of financial results or operational performance against industry benchmarks or specific comparable companies/projects. The transaction itself, an insider increasing stake, is a common occurrence across industries.

Related Party Transactions

• The acquisition of 154,799 shares by Manoira Corporation is considered a related party transaction as Manoira is indirectly controlled by Andrew Regan, who is the CEO, Director, and 10% owner of Conduit Pharmaceuticals Inc.
• Corvus Capital Ltd. (99% owner of Manoira) and Algo Holdings, Inc. (wholly owned subsidiary of Corvus) are also related parties through their connection to Andrew Regan.

Stakeholder Impact

• Shareholders: The increase in insider ownership may be perceived positively, signaling management's confidence and alignment of interests.
• Partners (Manoira Corporation): The joint development agreement signifies an ongoing strategic partnership.

Next Steps

• Continued execution of the joint development agreement between Conduit Pharmaceuticals Inc. and Manoira Corporation.

Key Dates

Recommendation

Keywords

Conduit Pharmaceuticals, CDT, Andrew Regan, Form 4, SEC Filing, Insider Trading, Beneficial Ownership, Stock Acquisition, Joint Development Agreement, Reverse Stock Split, Pharmaceuticals, Biotechnology